LAG3 and neoplasm: The phenomenon is most obvious in CD8+ TILs in which LAG-3 is highly expressed and combined with its ligand and is detected on the cancer cell surface, leading to the decline or exhaustion of T-cell function and thereby promoting tumour immune escape (36).